ArticleCureus2026
Sinus Laser-Assisted Closure Under Tumescent Local Anesthesia for Pilonidal Disease: A Pilot Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSinus laser-assisted closure (SiLaC) is a minimally invasive option for management of pilonidal sinus disease (PSD). Tumescent local anesthesia (TLA) may further facilitate outpatient treatment; however, its use in this setting has not been adequately studied. This pilot study aimed to assess the feasibility of SiLaC performed under TLA. MATERIALS AND
methodsBetween September 2025 and January 2026, 22 consecutive patients with PSD underwent SiLaC under TLA. Demographic characteristics, operative time, total volume of tumescent solution, and calculated lidocaine dose were recorded. Pain was assessed preoperatively, intraoperatively, and on postoperative days 1, 2, 3, and 7 using the Visual Analog Scale (VAS; 0-10). Postoperative complications and outpatient follow-up visits were documented, and early recurrence was assessed at 90 days within a predefined follow-up window of 90 ± 7 days.
resultsThe median age was 23 years (range, 18-62 years), and 19 of 22 patients were male. Median operative time was 30 minutes (range, 25-45 minutes), and median tumescent volume was 160 mL (range, 80-280 mL). Median VAS scores were 1 preoperatively (range, 1-2), 2 intraoperatively (range, 1-3), 3 on postoperative day 1 (range, 1-6), 2.5 on day 2 (range, 1-5), 2 on day 3 (range, 1-7), and 1 on day 7 (range, 1-2). Three minor postoperative events occurred: two cases of localized painful swelling and one case of minor bleeding. No anesthesia-related or major complications were observed. All 22 patients completed the 90-day follow-up; no patients were lost to follow-up, and no recurrences, wound healing disorders, or delayed complications were observed in the full evaluable cohort (0/22).
conclusionSiLaC performed under TLA appears feasible, well tolerated, and safe for appropriately selected patients in an outpatient setting. Given the small sample size, absence of a control group, and limited follow-up, larger prospective comparative studies with longer follow-up are needed to validate these findings and to determine whether TLA offers advantages over conventional local infiltration anesthesia, particularly in more extensive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.